CoChat

Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

Open access
Janku, Filip, Han, Sae-Won, Doi, Toshihiko, Amatu, Alessio, Ajani, Jaffer A., Kuboki, Yasutoshi, Cortez, Alex, Cellitti, Susan E., Mahling, Ping C., Subramanian, Kulandayan, Schoenfeld, Heidi A., Choi, Sarah M., Iaconis, Lori A., Lee, Lang Ho, Pelletier, Marc R., Dranoff, Glenn, Askoxylakis, Vasileios, Siena, Salvatore · 2022 · Cancer Immunology Research
Cited by 84

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Immune-stimulator antibody conjugates (ISAC) combining tumor-targeting monoclonal antibodies with immunostimulatory agents allow targeted delivery of immune activators into tumors. NJH395 is a novel, first-in-class ISAC comprising a Toll-like receptor 7 (TLR7) agonist conjugated to an anti-HER2 antibody via a noncleavable linker payload. Preclinical characterization showed ISAC-mediated activation of myeloid cells in the presence of antigen-expressing cancer cells, with antigen targeting and TLR7 agonism contributing to antitumor activity. Safety, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics were investigated in a phase I, multicenter, open-label study in patients with HER2+ non-breast advanced malignancies (NCT03696771). Data from 18 patients enrolled in single ascending dose escalation demonstrated delivery of the TLR7-agonist payload in HER2+ tumor cells and induction of type I IFN responses, which correlated with immune modulation in the tumor microenvironment. Cytokine release syndrome was a common, but manageable, drug-related adverse event. Antidrug antibodies and neuroinflammation at high doses represented significant clinical challenges. Data provide proof-of-mechanism and critical insights for novel immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-21-0722

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 84

Metadata

Authors
Janku, F., Han, S.-W., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P. C., Subramanian, K., Schoenfeld, H. A., Choi, S. M., Iaconis, L. A., Lee, L. H., Pelletier, M. R., Dranoff, G., Askoxylakis, V., & Siena, S.
Venue
Cancer Immunology Research
Published
2022-09-20
Volume
10
Issue
12
Pages
1441-1461
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W4297874939
Cited by
84
References
8
FWCI
4.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. https://app.cochat.ai/papers/10.1158/2326-6066.cir-21-0722
The paper
Janku, F., Han, S.-W., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P. C., Subramanian, K., Schoenfeld, H. A., Choi, S. M., Iaconis, L. A., Lee, L. H., Pelletier, M. R., Dranoff, G., Askoxylakis, V., & Siena, S. (2022). Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-21-0722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.